Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Regulatory Filings 2021

Apr 30, 2021

3535_rns_2021-04-30_00bb5df5-1ceb-495b-a5a2-8fb30627d124.html

Regulatory Filings

Open in viewer

Opens in your device viewer

Commercial update Aqua Bio Technology (ABT)

Commercial update Aqua Bio Technology (ABT)

30.4.2021 08:33:04 CEST | Aqua Bio Technology ASA | Non-regulatory press

releases

Products series from DCP Dermosciense (DCP)

Seidr and Seidr Cliniq have now passed all safety studies, which means that the

Seidr series (39 products in total) will be ready for distribution and sale in

q2 2021. See the first pictures from the series in Appendix 1.

Sister brand from Moana Skincare - B Natural

B Natural is based on the same unique ingredients as Moana Skincare and has been

created to adapt the product to other markets, expanding the commercial reach of

the unique Moana product line. The B Natural series (21 products in total ) is

ready for distribution and sale in q2 2021. See the first pictures from the

series in Appendix 1.

Update on new e-commerce website for ABT

ABT is launching a new e-commerce website in q2of 2021 containing all ABT

skincare products for shareholder and certain customers and will have B2B log in

for ABT's distributors

Restorsea's commercialization of ABT's hatching fluid ingredient (Aquabeautine

XL)

ABT's US partner Restorsea has invested large sums -

https://ir.lifemd.com/press-release-details.php#/?newsId=2114190 for the

exclusive right to use ABT's hatching fluid ingredient as the main ingredient in

its own and licensed products. As informed 8 of February 2021 -

https://newsweb.oslobors.no/message/524073 Hydrafacial officially announced its

partnership with Restorsea and launched in Q1 2021 its new Restorsea Lip Fix Kit

which is based on ABT's hatching fluid ingredient (Aquabeautine XL).

LifeMD (former Conversion Labs) presented NavaMD -

https://ir.lifemd.com/press-release-details.php#/?newsId=2205885 and its

cooperation with Restorsea in Q1 2021 and ABT expecting that the NavaMD products

containing Aquabeautine XL -

https://ir.lifemd.com/press-release-details.php#/?newsId=2114190 will be

launched in the near future.

The positive trend from Restorsea's commercialization of ABT's proprietary

technology increases the likelihood that ABT will receive additional renewal

payment and increased revenue from the sale of ingredients and royalties.

Pre launch of ABT`s products

ABT is planning a pre-launch of ABT's products in q2 and shareholders that would

like to learn more about the products and participate in the pre-launch should

subscribe and register on ABT`s website -

https://aquabiotechnology.com/pages/subscription to receive examples of our new

products.

For further information, please contact CEO Espen Kvale, telephone +47 9162

* * *

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. ABT's focus on commercialization and development of natural

ingredients and natural skin care products has been, and will continue to be, an

important part of the Company's strategy going forward.

Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock

Exchange.

This information was considered to be inside information pursuant to the EU

Market Abuse Regulation and is subject to the disclosure requirements pursuant

to section 5-12 of the Norwegian Securities Trading Act. The stock exchange

announcement was published by Håvard Lindstrøm, Head of Business Development, on

30 April 2021, at 08.30 CES

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Espen Kvale, CEO, +47 916 28 092, [email protected]

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/514/655/Download%20announcement%2

0as%20PDF.pdf

ABT stock exchange message appendix 30 April 2021.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/514/654/ABT%20stock%20exchange%20

message%20appendix%2030%20April%202021.pdf